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H.N.J.) and Reproductive and Developmental Sciences (H.O.D.C.), The Queen's Medical
Research Institute, Edinburgh EH16 4TJ, United Kingdom
Abstract
Prokineticin 1 (PROK1) is a recently described protein with a wide range of functions including
tissue-specific angiogenesis, modulation of inflammatory responses, and regulation of
hematopoiesis. The objective of this study was to investigate the role of PROK1 and prokineticin
receptor 1 (PROKR1) in human endometrium during early pregnancy. PROK1 and PROKR1
expression is significantly elevated in first-trimester decidua, compared with nonpregnant
endometrium. Expression of PROK1 and PROKR1 was localized in glandular epithelial and
various cellular compartments within the stroma. To investigate the signaling pathways and target
genes activated by PROK1, we generated an endometrial epithelial cell line stably expressing
PROKR1 (Ishikawa PROKR1 cells). PROK1-PROKR1 interaction induced inositol phosphate
mobilization and sequential phosphorylation of c-Src, epidermal growth factor receptor, and ERK
1/2. Gene microarray analysis on RNA extracted from Ishikawa PROKR1 cells treated with 40 nM
PROK1 for 8 h revealed 49 genes to be differentially regulated. A number of these genes,
including cyclooxygenase (COX)-2, leukemia inhibitory factor, IL-6, IL-8, and IL-11 are
regulated in the endometrium during implantation and early pregnancy. We subsequently
investigated the effect of PROK1 on expression of COX-2 in Ishikawa PROKR1 cells and first-
trimester decidua. COX-2 mRNA and protein expression, and prostaglandin synthesis, were
elevated in response to treatment with PROK1. Moreover, expression of COX-2 by PROK1 was
dependent on activation of the Gq-phospholipase C-β-cSrc-epidermal growth factor receptor-
MAPK/ERK kinase pathway. These data demonstrate that PROK1 and PROKR1 expression is
elevated in human decidua during early pregnancy and that PROK1-PROKR1 interaction
regulates expression of a host of implantation-related genes.
Prokineticins are secreted proteins with pleiotropic functions in human and animal tissues.
They comprise prokineticin (PROK)-1 or endocrine gland-vascular endothelial growth
factor (1, 2) and PROK2 or Bv8 (3). The receptors for prokineticins are two closely related
G protein-coupled receptors, prokineticin receptor (PROKR)-1 and PROKR2 (4, 5).
Structure-function analysis have highlighted that the prokineticin N-terminal amino acid
sequence, AVITGA, is completely conserved and essential to their activity (6, 7).
Expression and regulation of the prokineticins has been described in human endometrium
and early pregnancy tissues. PROK1 but not PROK2 displays differential expression across
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the menstrual cycle with elevation in the secretory phase (8, 9), and expression of PROK1 is
known to be regulated by steroid hormones (8, 9). However, PROKR1 and PROKR2 mRNA
expression does not change across the menstrual cycle, and little is known about their mode
of regulation. PROK1 and PROK2 localize to the glandular and luminal epithelium,
endothelial, and stromal cells of the endometrium (8). Similarly, PROKR1 localizes to the
glandular and luminal epithelium, endothelial, and stromal cells in the functional layer of the
endometrium (8). PROK1 and PROKR1 expression have also been reported to change in
placental tissues during early pregnancy with elevation between wk 8 and 9 of gestation
(10). PROK1 localizes to the syncytiotrophoblast and cytotrophoblast layers (10), whereas
PROKR1 expression remains to be investigated.
We demonstrate elevated expression of PROK1 and PROKR1 in first-trimester decidua,
compared with nonpregnant endometrium. Expression of both proteins in first-trimester
decidua localized to glandular epithelium and endothelial cells of the microvasculature.
Additionally, PROK1 but not PROKR1 was detected in uterine natural killer cells.
Treatment of endometrial epithelial Ishikawa cells stably transfected with PROKR1 with
PROK1 resulted in inositol phosphate production and phosphorylation of cSrc, epidermal
growth factor receptor (EGFR), and ERK1/2. Gene array analysis of these cells treated with
PROK1 identified 49 PROK1-PROKR1 regulated genes. These included genes known to
function in regulation of implantation, such as cyclooxygenase (COX)-2, leukemia
inhibitory factor (LIF), and IL-11. We subsequently established that PROK1 elevates
expression of COX-2 via a Gq-phospholipase C (PLC)-β-cSRC-EGFR-ERK1/2 pathway in
PROKR1-Ishikawa cells and first-trimester decidua.
Materials and Methods
Reagents
DMEM F-12 Glutamax culture medium was purchased from Invitrogen Life Technologies
(Paisley, UK). Phosphotyrosine, c-Myc, phospho-cSrcY418, phospho-EGFR, β-actin, and
COX-2 antibodies were purchased from Santa Cruz Biotechnology/Autogen Bioclear
(Wiltshire, UK). Phospho-ERK and total-ERK antibodies were purchased from Cell
Signaling Technologies (Hertfordshire, UK). Prokineticin 1 antibody was purchased from
Phoenix Pharmaceuticals (Belmont, CA). Prokineticin receptor 1 antibody was purchased
from Lifespan Biosciences (Atlanta, GA). Alkaline phosphatase secondary antibodies and
BSA were purchased from Sigma (Dorset, UK). Superfect transfection reagent was
purchased from QIAGEN (Crawley, UK). Tritiated myo-inositol and enhanced
chemifluorescence were purchased from Amersham (Little Chalfont, Buckinghamshire,
UK). Fluorescent secondary antibodies were purchased from Li-Cor Biosciences UK Ltd.
(Cambridge, UK). PLC inhibitor (U73122, final concentration 10 μm), cSrc inhibitor [4-
amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine (PP2), final concentration
10 μm], EGFR inhibitor (AG1478, final concentration 200 nm), MAPK kinase (MEK)
inhibitor (PD98059, final concentration 50 μm), and COX-2 inhibitor (NS-398, final
concentration 10 μm) were purchased from Calbiochem (Nottingham, UK). Gq inhibitor
(YM254890, final concentration 1 μm) was kindly supplied by Dr. Jun Takasaki (Molecular
Medicine Laboratories, Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan). Recombinant
human PROK1 was purchased from Promokine (Heidelberg, Germany).
Patients and tissue collection
Endometrial biopsies (n = 51) were obtained from women with regular menstrual cycles
(25–35 d) who had not received hormonal preparation in the 3 months preceding biopsy
collection and dated according to histological assessment by a pathologist. Furthermore,
circulating estradiol and progesterone concentrations were consistent for both stated last
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menstrual period and histological assessment of menstrual cycle stage. First-trimester
decidua (7–12 wk, n = 33) was collected from women undergoing elective first-trimester
surgical termination of pregnancy. Ethical approval was obtained from Lothian Research
Ethics Committee, and written informed consent obtained before tissue collection.
Cell/tissue culture and treatment
Ishikawa endometrial epithelial cells obtained from the European Collection of Cell Culture
(Health Protection Agency, Porton Down, Wiltshire, UK) were routinely maintained in
DMEM F-12 Glutamax culture medium with 10% fetal bovine serum, 100 IU penicillin, and
100 μg streptomycin at 37 C and 5% CO2 as of recommended, with addition 200 μg/ml
G418 to culture medium of stably transfected cells. First-trimester decidua tissue for explant
studies (n = 24) was isolated at surgical termination of pregnancy. Tissue explants were
chopped finely with scissors and maintained in DMEM. Tissue was divided into equal
portions for experimental procedures.
To produce PROKR1-Ishikawa cells, human receptor cDNA was amplified using Easy-A
DNA polymerase (Stratagene, La Jolla, CA) and specific primers: forward; 5′-GGA TCC
AGG CTT GAT GGA GAC CAC CAT GGG G-3′, reverse; 5′-CTC GAG GAT ATC TTT
TAG TCT GAT GCA GTC CAC CT-3′. The PCR product was gel purified, ligated into
sequencing vector pCR4 (Invitrogen) and cloned into Escherichia coli TOP10 cells. Cloned
plasmid DNA was sequenced before subcloning into pcDNA3.1(+), transfected into
Ishikawa cells using electroporation, and G418-resistant clones isolated. A selected clone
was characterized for PROKR1 expression by PCR and activation of signaling. Transient
transfections were performed using Myc-tagged ERK and dominant-negative (DN) isoforms
of cSrc, EGFR, Ras, and MEK (kindly donated by Professor Zvi Naor, Department of
Biochemistry, Tel Aviv University, Tel Aviv, Israel).
Cells and tissue were incubated in serum-free medium overnight before treatment with
PROK1 alone or in the presence of inhibitors, at concentrations indicated above, with
pretreatment for 1 h (8). Cells and tissue were harvested and RNA or protein extracted for
PCR and Western immunoblot analysis. Cells cotransfected with Myc-tagged ERK and DN
were subjected to immunoprecipitation before Western immunoblot analysis.
Total inositol phosphate assay
Accumulation of total inositol phosphates in the presence of Li+ was measured in wild-type
(WT) and PROKR1-Ishikawa cells, preloaded with [3H]myo-inositol and subsequently
treated with PROK1, according to published protocols (11).
Immunohistochemistry and immunofluorescent microscopy
Five-micrometer paraffin-embedded sections were dewaxed and rehydrated in graded
ethanol. Sections were incubated overnight at 4 C with rabbit antihuman PROK1 (1:1000) or
rabbit antihuman PROKR1 (1:250). An avidin-biotin peroxidase detection system was
applied (Dako Ltd., Cambridge, UK) with 3,3′-diaminobenzidine as the chromagen.
Colocalization of PROKR1 with COX-2 or CD31 (endothelial cell marker) and PROK1
with CD56 (natural killer cell marker) were performed by dual-immunofluorescence
histochemistry. Sections were prepared and blocked using 5% normal horse serum
(PROKR1/COX-2) or 5% normal goat serum (PROK1/CD56 and PROKR1/CD31).
Sections were incubated with goat anti-COX-2 antibody (1:50), mouse anti-CD56 (1:250),
or mouse anti-CD31 (1:20) overnight at 4 C. Subsequently sections were incubated with
biotinylated antibodies, followed by incubation with fluorochromes streptavidin 488 or 546
(1:200 in PBS). Sections were reblocked with 5% normal goat serum and incubated with
rabbit anti-human PROK1 (1:1500) or rabbit antihuman PROKR1 (1:500) overnight at 4 C.
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Negative control sections were incubated with rabbit IgG. Sections were incubated with
peroxidase goat antirabbit (1:200 in PBS) followed by fluorochromes TSA-plus fluorescein
(PerkinElmer, Applied Biosystems, Warrington, UK) or cyanine-3 (1:50 in substrate).
Sections were washed and incubated with nuclear counterstain ToPro (1:2000 in PBS),
mounted in Permafluor, coverslipped, visualized, and photographed using a laser-scanning
microscope (LSM 510; Carl Zeiss, Jena, Germany) using a 40 × 1.4 aperture oil immersion
lens.
Taqman quantitative RT-PCR
RNA was extracted with TRI reagent (Sigma) following the manufacturer's guidelines using
phase lock tubes (Eppendorf, Cambridge, UK). RNA samples were reverse transcribed as
described (6). PCRs were carried out using an ABI Prism 7700 (Applied Biosystems, Foster
City, CA). Primer and FAM (6-carboxyfluorescein)-labeled probe sequences are supplied in
Table 1. Gene expression was normalized to RNA loading using primers and VIC (Applied
Biosystems)-labeled probe for ribosomal 18s as an internal standard. Results are expressed
as relative to a positive RNA standard (cDNA obtained from a single endometrial tissue)
included in all reactions.
PCR analysis
PROK1 and PROKR1 expression in uterine natural killer (uNK) cells was assessed by
conventional RT-PCR. Natural killer cells were isolated from first-trimester decidua
according to published protocols (12). RNA was extracted, reverse transcribed, and cDNA
subjected to PCR analysis with specific primers for PROK1 and PROKR1: PROK1 forward,
5′-GTG CCA CCC GGG CAG-3′; PROK1 reverse, 5′-AGC AAG GAC AGG TGT GGT
GC-3′; PROKR1 forward, 5′-GGA TCC AGG CTT GAT GGA GAC CAC CAT GGG
G-3′; PROKR1 reverse, 5′-CTC GAG GAT ATC TTT TAG TCT GAT GCA GTC CAC
CT-3′. cDNA prepared from human endometrium with/without reverse transcriptase
enzyme was positive and negative controls, respectively. PCR products were run on a 1%
agarose gel.
Protein extraction and Western immunoblot analysis
Cells/tissue were harvested in Nonidet P-40 lysis buffer and protein content quantified (Bio-
Rad Laboratories, Hemel Hempstead, UK). Proteins (40 μg) were solubilized in Laemmli
buffer and boiled for 5 min. For immunoprecipitation experiments, 1 mg of lysate was
incubated with antiphosphotyrosine agarose preconjugated slurry or anti-Myc agarose
preconjugated slurry overnight at 4 C and solubilized as above. Proteins were resolved,
blotted, incubated with specific primary antibodies, visualized by ECF or direct fluorescent
system, and quantified by phosphorimager analysis (Typhoon 9400 system; Amersham) or
infrared imaging system (Odyssey; LiCor). To account for variability in protein loading,
phosphorylation of protein was normalized by dividing the value obtained from the
phosphorylated blots by the value obtained from the total ERK (for ERK Westerns) or light-
chain IgG blots (for cSrc and EGFR Westerns). Relative density of COX-2 blot was
normalized against β-actin.
Gene array
PROKR1-Ishikawa cells were treated with vehicle or 40 nm PROK1 for 8 h. RNA was
extracted and hybridized to GeneChip Human Genome U133 plus 2.0 (Affymetrix, High
Wycombe, UK) and AB1700 version 2 Applied Biosystems Human Genome Survey
microarrays. After hybridization the GeneChip arrays were stained and washed on the
fluidics station and scanned.
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Gene array data analysis
Cross-mapping between AB1700 probes and Affymetrix probe sets was courtesy provided
by Applied Biosystems. Data acquired using ABI technology were preprocessed according
to the manufacturers' recommendations. The data for both platforms were normalized using
variance stabilized normalization (13). Normalized data were analyzed for differential
expression with the LIMMA package as described in the LIMMA user guide (14). The P
values were adjusted for multiple testing with Benjamini and Hochberg method (15). The
resulting gene list included only the genes that had a fold change value of 1.5 or higher and a
P < 0.05. Bioinformatics was performed using the gene set analysis tool kit (16). A
hypergeometric test was used to calculate significantly over-represented ontologies from the
gene list.
Prostaglandin (PG)-E2 and PGF2α measurement
PROKR1-Ishikawa cells were treated with 40 nm PROK1 alone or in the presence of
COX-2 inhibitor NS398 with the addition of 3 μg/ml arachidonic acid. Medium was
removed and assayed by ELISA for PGE2 and PGF2α (17). Data are presented as fold above
vehicle-treated control.
Statistics
Data were subjected to statistical analysis with ANOVA and Fisher's protected least
significant difference tests (Statview 5.0; Abacus Concepts Inc., Berkeley, CA).
Results
Expression of PROK1 and PROKR1 in cycling endometrium and first-trimester decidua
PROK1 mRNA expression was significantly elevated in the secretory phase of the menstrual
cycle, compared with the proliferative phase (P < 0.05, Fig. 1A), whereas PROKR1
expression did not vary (Fig. 1B). mRNA expression of both PROK1 and PROKR1 in first-
trimester decidua was elevated, compared with nonpregnant endometrium (P < 0.001, Fig. 1,
A and B, respectively). PROK1 and PROKR1 protein localize to glandular epithelium,
stroma, and vascular endothelial cells of first-trimester decidua (Fig. 1, C and D, PROK1
and PROKR1, respectively), similar to the localization reported for PROK1 and PROKR1 in
nonpregnant endometrium (8). Expression of PROK1 and CD56 (a marker of natural killer
cells) or PROKR1 and CD31 (a marker of endothelial cells) were colocalized (Fig. 1, E and
F, respectively) in the decidualized endometrium. Expression of PROK1 in uNK cells within
the pregnant endometrium was confirmed by RT-PCR analysis. A PCR band of the expected
size for PROK1 (328 bp) was amplified from cDNA prepared using RNA from uNK cells
isolated from three individual first-trimester decidual tissues (Fig. 1G). PROKR1 expression
was not detected in uNK cells by PCR analysis or immunohistochemical colocalization (data
not shown).
PROK1 via PROKR1 induces ERK 1/2 phosphorylation via a cSrc and EGFR dependent
pathway
To investigate signaling and gene activation upon PROKR1 activation, Ishikawa cells were
stably transfected with PROKR1 cDNA. Real-time PCR revealed elevation (~35-fold) of
PROKR1 mRNA in these cells, compared with wild-type Ishikawa cells (Fig. 2A).
Immunofluorescent histochemistry demonstrates differential expression of PROKR1 in
PROKR1 Ishikawa cells, compared with WT Ishikawa cells (Fig. 2A). PROKR1 is thought
to couple to Gq and therefore activate PLC (4). We therefore measured total inositol
phosphate (IP3) accumulation in WT and PROKR1-Ishikawa cells after PROK1 treatment.
There was no increase in IP3 production in WT Ishikawa cells; however, IP3 production in
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PROKR1-Ishikawa cells was significantly elevated after treatment with 40 nm PROK1 (2.71
± 0.25-fold above vehicle-treated control, P < 0.05, Fig. 2B). We subsequently assessed the
effect of PROK1 on the activation of ERK 1/2. Phosphorylation of ERK 1/2 in PROKR1-
Ishikawa cells was observed after treatment with 40 nm PROK1 (5.21 ± 0.52-fold above
vehicle-treated control, P < 0.001, Fig. 2C). Phosphorylation of ERK 1/2 in response to 40
nm PROK1 was maximal within 5–10 min and declined by 20 min (Fig. 2D).
We investigated the intracellular signaling mechanism of ERK 1/2 phosphorylation by
PROK1-PROKR1 activation. PROK1-induced ERK 1/2 phosphorylation at 5 min (Fig. 2E,
lane 2) was abolished by cotreatment with Gq inhibitor (Fig. 2E, lane 3), PLC-β inhibitor
(Fig. 2E, lane 4), cSrc inhibitor (Fig. 2E, lane 5), EGFR inhibitor (Fig. 2E, lane 6), or MEK
inhibitor (Fig. 2E, lane 7). PROK1-induced ERK 1/2 phosphorylation was not inhibited on
cotreatment with pertussis toxin (data not shown). Transient cotransfection of PROKR1-
Ishikawa cells with a Myc-tagged ERK cDNA construct and empty vector (pcDNA3) or
cDNA encoding DN isoforms of cSrc, EGFR, Ras, or MEK also significantly reduced
PROK1-induced elevation of Myc-tagged ERK phosphorylation at 5 min (Fig. 2F, P <
0.001).
Treatment of PROKR1-Ishikawa cells with 40 nm PROK1 induced rapid phosphorylation of
both cSrc (Fig. 2G) and EGFR (Fig. 2H), which peaked at 5 min (3.61 ± 0.8- and 2.02 ±
0.27-fold above vehicle-treated control for cSrc and EGFR phosphorylation respectively, P
< 0.05).
PROK1 induces expression of genes with established roles in implantation
To examine gene expression regulated by PROK1, PROKR1-Ishikawa cells were treated
with 40 nm PROK1 or vehicle for 8 h (three independent experiments). RNA was extracted,
hybridized to AB1700 and Affymetrix gene chips, and subjected to gene array analysis. We
identified 46 up- and three down-regulated genes yielding fold changes of more than 1.5-
fold on both platforms with an adjusted P ≤ 0.05 on at least one of the platforms (Table 2).
Five genes were selected to verify gene array data by real-time PCR. Basal level of
expression of these genes was not different in WT, compared with PROKR1 Ishikawa cells.
However, PROK1 treatment of PROKR1-Ishikawa cells for 8 h confirmed the elevation
observed in the arrays for COX-2 (4.8 ± 1.2-fold), LIF (12.4 ± 3.5-fold), IL-6 (15.55 ± 1.8-
fold), IL-8 (152 ± 81.1-fold), and IL-11 (249.6 ± 88.3-fold). No increase in gene expression
was detected in WT Ishikawa cells (Fig. 3). It has been demonstrated that gene array
analysis has a dynamic range of around 3 orders of magnitude, compared with a dynamic
range of around 7 orders of magnitude for Taqman real-time PCR based analysis (18). This
confers a higher detection sensitivity on Taqman PCR-based analysis. Additionally, it is
well recognized that due to technical limitations associated with the amount of bound DNA,
array analysis can result in an underestimation of differential gene expression (19). The
difference in fold change observed with IL-8 and IL-11 between array vs. PCR analysis is
therefore likely due to the smaller dynamic range of the gene array at large fold changes,
compared with high dynamic range of PCR-based analysis.
PROK1 induces COX-2 expression and prostaglandin production in PROKR1-Ishikawa
cells and first-trimester decidua
COX-2 plays a role in mouse decidualization and is regulated during the human menstrual
cycle. We therefore investigated the temporal regulation and mechanism of COX-2
expression induced by PROK1. Treatment of PROKR1-Ishikawa cells with 40 nm PROK1
resulted in a time-dependent increase in COX-2 mRNA and protein expression with a peak
observed at 6 h (6.9 ± 1.2-fold increase above vehicle treated control, P < 0.01, Fig. 4A) and
8 h, respectively (9.59 ± 2.1-fold increase above vehicle treated control, P < 0.01, Fig. 4B).
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No increase in COX-2 mRNA expression was observed in the WT Ishikawa cells in
response to PROK1 (Fig. 4A). PROK1-induced COX-2 protein expression at 8 h (Fig. 4C,
lane 2) was significantly inhibited (P < 0.001) on cotreatment with inhibitors of Gq (Fig. 4C,
lane 3), PLC-β (Fig. 4C, lane 4), cSrc (Fig. 4C, lane 5), EGFR (Fig. 4C, lane 6), or MEK
(Fig. 4C, lane 7).
Downstream of PROK1-mediated COX-2 expression, de novo PGE2 and PGF2α production
were significantly elevated in response to PROK1 with maximal concentration of both
prostaglandins detected 12 h after treatment with 40 nm PROK1, compared with vehicle-
treated cells (15.3 ± 2.9- and 5.3 ± 0.5-fold increase for PGE2 and PGF2α respectively, Fig.
4, D and E, P < 0.001). Cotreatment of PROKR1-Ishikawa cells with PROK1 and NS-398, a
specific COX-2 inhibitor, abolished synthesis of both prostaglandins.
Potential regulation of COX-2 by PROK1 in the human endometrium and first-trimester
decidua was subsequently investigated. COX-2 (green channel) and PROKR1 (red channel)
expression were colocalized (PROKR1/COX-2, yellow channel) to glandular epithelium and
some stromal cells (Fig. 5A) within human endometrium and first-trimester decidua. To
correlate our findings in the PROKR1-Ishikawa cell line, we investigated PROK1 signaling
in first-trimester decidua tissue explants. Upon treatment with 40 nm PROK1, maximal
phosphorylation of ERK 1/2 in decidua explants was observed at 30–45 min (3.8 ± 0.7- and
3.9 ± 1.2-fold above vehicle treated controls, respectively, P < 0.01, Fig. 5B). Elevation of
PROK1-induced ERK 1/2 in decidua explants at 30 min (Fig. 5C, lane 2) was significantly
inhibited (P < 0.001) on cotreatment with inhibitors of Gq (Fig. 5C, lane 3), PLC-β (Fig. 5C,
lane 4), cSrc (Fig. 5C, lane 5), EGFR (Fig. 5C, lane 6), or MEK (Fig. 5C, lane 7).
Treatment of first-trimester decidua with 40 nm PROK1 revealed time-dependent regulation
of COX-2 mRNA expression in decidua with a peak at 6 h (2.7 ± 0.5-fold above vehicle-
treated control, P < 0.05, Fig. 5D). PROK1-induced expression of COX-2 at 6 h (Fig. 5E,
lane 2) was significantly reduced (P < 0.001) by cotreatment of tissue explants with Gq
inhibitor (Fig. 5E, lane 3), PLC-β inhibitor (Fig. 5E, lane 4), cSrc inhibitor (Fig. 5E, lane 5),
EGFR inhibitor (Fig. 5E, lane 6), or MEK inhibitor (Fig. 5E, lane 7).
Discussion
Our data confirm previous reports that PROK1 mRNA expression peaks in the secretory
phase of the menstrual cycle, whereas PROKR1 expression does not alter significantly
across the cycle (8). Expression of PROK1 and PROKR1 in first-trimester decidua samples
taken from 7–12 wk of gestation is significantly elevated, compared with all phases of the
menstrual cycle. Elevation of PROK1 and PROKR1 in early pregnancy has been highlighted
previously in which expression of both factors has been observed in early placental tissues
(10). Both PROK1 and PROKR1 localized to glandular epithelial cells and stromal cells.
Within the stroma, PROKR1 was localized to endothelial cells, suggesting a role for
PROK1/PROKR1 in regulation of vascular function. Indeed, delivery of PROK1 has been
shown to induce neovascularization in the mouse ovary (2). A subset of stromal cells
expressing PROK1 were characterized as natural killer cells by CD56 staining. These cells
are also known to cluster around the blood vessels in the endometrium and have been
suggested to regulate vascular function (20).
To elucidate intracellular signal transduction pathways mediating the effects of PROK1 via
PROKR1 in the endometrium, an endometrial epithelial model cell line stably expressing
human PROKR1 was used. Prokineticin receptors are reported to couple to Gi or Gq (4, 5,
21). We demonstrated elevation of inositol phosphate mobilization on stimulation of
PROKR1 cells with PROK1, indicating Gq coupling in this system. PLC activation leads to
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activation of downstream phosphorylation cascades, and MAPK phosphorylation has been
implicated in signaling downstream of PROKR1 activation (21). Transient phosphorylation
of ERK 1/2 was demonstrated on PROKR1 activation in PROKR1-Ishikawa cells and first-
trimester decidua tissue, which peaked at 5 and 30 min, respectively. These differences are
possibly due to different levels of receptor expression, the presence of heterogeneous cells,
and the thickness of the tissue pieces into which the ligand must penetrate in the explant
culture, compared with the homogenous cell population of PROKR1-Ishikawa cells.
Signaling to ERK1/2 upon G protein-coupled receptor activation involves intracellular
phosphorylation cascades (22). PROK1-induced ERK 1/2 phosphorylation was
demonstrated, by using chemical inhibitors, to be dependent on activation of Gq, PLC-β,
cSrc, EGFR, and MEK phosphorylation, but not Gi activation, in both PROKR1-Ishikawa
cells and decidua tissue. Furthermore, phosphorylation of cSrc and EGFR in response to
PROK1 peaks within the time frame of maximal ERK 1/2 phosphorylation. Similarly, DN-
cSrc, DN-EGFR, DN-Ras, and DN-MEK inhibited PROK1 mediated ERK 1/2
phosphorylation, confirming the role of these molecules in signaling to ERK 1/2.
Global gene profiling was conducted on two different array platforms to elucidate potential
functions of PROKR1. Analysis of the combined array platforms revealed differential
expression of 49 genes after PROK1 stimulation. Five genes up-regulated in the arrays were
selected to verify the changes by real-time PCR. IL-11, IL-8, IL-6, LIF, and COX-2 (PG-
endoperoxidase synthase 2) confirmed gene array fold changes after PROK1 stimulation.
Analysis of the expressed sequence tag tissue library database (16) indicated that genes
whose expression is regulated by PROK1 are significantly overexpressed in uterine tissue,
compared with other tissue libraries. These data may suggest that, although the data are
obtained from in vitro studies using an immortalized cell line, the response is likely to be
representative of a uterine cell. Indeed, analysis of gene expression induced by PROK1 in
first-trimester decidua tissue demonstrates similarity in regulation of target genes by PROK1
in Ishikawa cells and first-trimester deciduas. Analysis of the gene list for Gene Ontology
annotations indicated roles for PROK1 in regulating genes involved in responses to
wounding (inflammation and angiogenesis) and cellular proliferation. These processes are of
importance in the endometrial response to implantation. Little is known about the direct role
for PROK1 in implantation; however, a host of genes identified in this study to be regulated
by PROK1 include those with known roles in endometrial receptivity. For example, PROK1
regulated genes independently validated by Taqman quantitative PCR; LIF, COX-2, IL-6,
and IL-11, have suggested roles in implantation and decidualization (23-26).
Other PROK1-regulated genes with known roles in implantation include members of the
epidermal growth factor (EGF) family, namely amphiregulin and heparin binding-EGF
(diptheria toxin receptor). Mice null for uterine heparin binding-EGF display reduced
numbers of implantation sites and reduced litter sizes; however, it was observed that
amphiregulin displayed compensatory up-regulation in this model (27). Amphiregulin is
expressed in the luminal epithelium of the mouse at the onset of blastocyst attachment (28)
and is expressed in the decidual area in the hamster (29). Other genes with suggested roles in
implantation include Dickkopf-1, CD44, and CD55. Expression of these factors has been
reported in the human endometrium during the window of implantation and has been
highlighted in array studies of human endometrium during the window of implantation
(30-37). CD55, also known as decay accelerating factor, has also been shown to be down-
regulated in antiphospholipid syndrome, a condition associated with recurrent miscarriage
(38). CD44 has a proposed role in angiogenesis (39), whereas CD55 is proposed to exert
endothelial cytoprotection during inflammatory angiogenesis (40, 41).
We subsequently elucidated the mechanism by which PROK1-PROKR1 regulates COX-2
expression in PROKR1 Ishikawa cells and first-trimester decidua tissue. COX-2 is important
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in regulation of the decidual response (42), and COX-2 localizes to luminal and glandular
epithelial cells in human endometrium (43). Differentiation of endometrial stromal cells into
decidua is mediated by PGE2 synthesis through elevation of COX-2. PROK1 action may be
important in PGE2-driven changes in decidualized endometrium. We demonstrate that
PROKR1 and COX-2 colocalize to glandular epithelial and stromal cells of midsecretory
endometrium and first-trimester decidua. This suggests potential regulation of COX-2
expression by PROK1 in both compartments during endometrial receptivity and early
pregnancy. PROK1-PROKR1 rapidly induces COX-2 expression via a cascade of signaling
molecules: Gq, PLC, Ca2+, cSrc, EGFR, and MEK. Induction of COX-2 appears to be
dependent on EGFR transactivation. EGF-mediated signaling is proposed to regulate COX-2
expression in mouse models (44).
PROK1-PROKR1 activation induced secretion of prostaglandins via COX-2 because the
inhibitor NS-398 abolished prostaglandin production. Blastocyst attachment in mice
coincides with a highly localized increase in vascular permeability associated with increased
adhesiveness of the endometrium. This has been associated with expression of COX-2 (45),
PGE2 synthase, PGE2 secretion, and E-prostanoid (EP) receptors at the implantation site
(46-48). Edema and increased vascular permeability is also evident in the human
endometrium at the time of implantation (49). In COX-2-deficient mice, there is impaired
vascular permeability at the site of blastocyst apposition (50), possibly due to a deficiency in
prostaglandin-influenced uterine angiogenesis (51). The defects in the COX-2-deficient
mouse are rescued on administration of stable analogs of PGI2 (24), which is the most
abundant prostaglandin in the mouse uterus at the time of implantation (24). However, the
human endometrium produces little PGI2 (52), and it is suggested that PGE2-mediated
action may be more important in the human (53, 54). PROK1 may therefore play a role in
the prostaglandin-directed increase in endometrial vascular permeability. The trophoblast
also strongly expresses PROK1 (10), indicating that the trophoblast may promote enhanced
PGE2 synthesis in the decidualized endometrium, creating a favorable environment for
implantation. Uterine natural killer cells also may cooperate with trophoblast cells to
modulate remodeling of spiral arterioles during implantation. This is supported by the
demonstration of expression of PROK1 in uNK cells and PROKR1 in trophoblast cells (10).
In conclusion, we propose that PROK1-PROKR1 regulates the expression of a host of genes
that are involved in the establishment and maintenance of pregnancy. PROK1-PROKR1
signaling induces the expression of target genes, such as COX-2, via cross talk with the
EGFR and downstream phosphorylation of ERK 1/2.
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FIG. 1.
Temporal expression and localization of PROK1 and PROKR1 in human endometrium and
first-trimester decidua. PROK1 (A) and PROKR1 (B) mRNA expression in endometrium
and first-trimester decidua are shown. EP, Early proliferative, MP, mid proliferative, LP,
Late proliferative; ES, early secretory; MS, midsecretory; LS, late secretory (sample size
from each stage of the cycle is depicted in the figure). In first-trimester deciduas, PROK1
and PROKR1 expression (n = 7; representative sections shown in C and D, respectively)
localize to the glandular epithelium (G), stromal cells (S), and vascular endothelial cells (E)
of the microvasculature (×10 magnification, inset, black box, ×20 magnification). E, A
population of PROK1-expressing stromal cells were identified as natural killer cells by
immunofluorescent histochemistry and confocal microscopy for CD56 (natural killer cell
marker, red panel) and PROK1 (green panel) by co-localization (yellow channel). This was
confirmed by conventional PCR (G) conducted using natural killer cell RNA isolated from
individual decidua tissue (n = 3). PROKR1 localization to endothelial cells was confirmed
by double-immunofluorescent histochemistry (F) for CD31 (endothelial cell marker, red
panel) and PROKR1 (green panel) by colocalization (yellow channel). Data are shown as
mean ± SEM (*, P < 0.05; **, P < 0.001). Negative control (−ve) is indicated in the figure.
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FIG. 2.
Expression of PROKR1 in PR OKR1-Ishikawa cells and signaling induced by PROKR1 via
PROK1. A, PROKR1 RNA expression is significantly elevated in PROKR1-Ishikawa cells,
compared with WT Ishikawa cells as assessed by real-time PCR analysis. Similarly,
immunofluorescent histochemistry demonstrates expression of PROKR1 protein (red
staining) in PROKR1-Ishikawa cells, which is absent in WT Ishikawa cells. B, Inositol
phosphate mobilization is elevated in PROKR1, compared with WT Ishikawa cells after
treatment with 40 nM PROK1. C, ERK1/2 phosphorylation was determined by Western blot
analysis; phosphorylation is maximal in PROKR1-Ishikawa cells after treatment with 40 nM
PROK1. D, ERK1/2 phosphorylation in PROKR1-Ishikawa cells incubated with 40 nM
PROK1 is maximal at 5 min. E, ERK 1/2 phosphorylation was measured in PROKR1-
Ishikawa cells in response to the administration of vehicle or 40 nM PROK1 for 5 min in the
presence or absence of pretreatment with YM254890 (Gq inhibitor, lane 3), U73122 (PLC
inhibitor, lane 4), PP2 (cSrc inhibitor, lane 5), AG1478 (EGFR inhibitor, lane 6), or
PD98059 (MEK inhibitor, lane 7). The PROK1-induced ERK 1/2 response was significantly
inhibited in the presence of these inhibitors. F, PROKR1-Ishikawa cells were transiently
cotransfected with Myc-tagged ERK and either empty vector (pcDNA3) or cDNA constructs
encoding DN isoforms of cSrc, EGFR, Ras, or MEK. Transfected cells were subjected to
stimulation with vehicle or 40 nM PROK1 for 5 min. PROK1-induced ERK response was
significantly inhibited by the DN cDNA constructs. G and H, cSrc and EGFR
phosphorylation is increased in PROKR1-Ishikawa cells after treatment with 40 nM
PROK1. The PROK1-induced cSrc and EGFR phosphorylation peaked at 5 min. ERK1/2,
cSrc and EGFR phosphorylation was calculated as fold above vehicle-treated controls. For
each, a representative Western immunoblot is shown with semiquantitative analysis
determined as described in Materials and Methods. In all panels each bar represents the
mean ± SEM of at least three individual experiments (*, P < 0.05). −, Absence of agent; +,
presence of agent.
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FIG. 3.
Validation of gene array analysis by real-time PCR. Expression of COX-2 (PTGS2), LIF,
IL-6, IL-8, and IL-11 is significantly elevated in PROKR1-Ishikawa cells stimulated with 40
nM PROK1 for 8 h. No elevation was observed in WT Ishikawa cells. Each bar represents
the mean ± SEM of at least three individual experiments (*, P < 0.05; **, P < 0.01).
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FIG. 4.
PROK1-induced COX-2 mRNA expression is mediated via ERK 1/2 and results in de novo
synthesis of prostanoids. A, COX-2 expression in WT and PROKR1-Ishikawa cells after
treatment with 40 nM PROK1. No elevation in COX-2 mRNA expression was observed in
WT Ishikawa cells, whereas COX-2 expression peaked at 6 h in PROKR1-Ishikawa cells. B,
COX-2 protein expression, as determined by Western blot analysis, was maximal in
PROKR1-Ishikawa cells after treatment with 40 nM PROK1 (p) for 8 h. No elevation in
COX-2 protein expression was observed in vehicle (v)-treated cells. C, COX-2 protein
expression was measured in PROKR1-Ishikawa cells in response to the administration of
vehicle or 40 nM PROK1 for 8 h in the presence or absence of pretreatment with
YM254890 (Gq inhibitor, lane 3), U73122 (PLC inhibitor, lane 4), PP2 (cSrc inhibitor, lane
5), AG1478 (EGFR inhibitor, lane 6), or PD98059 (MEK inhibitor, lane 7). The PROK1-
induced COX-2 expression was significantly inhibited in the presence of these inhibitors.
PROK1-induced de novo synthesis of PGF2α (D) and PGE2 (E) is COX-2 dependent,
indicated by abrogation of prostaglandin production in presence of specific COX-2 inhibitor
NS-398. For B and C, a representative Western immunoblot is shown with semiquantitative
analysis determined as described in Materials and Methods. In all panels each bar represents
the mean ± SEM of at least three independent experiments (*, P < 0.05). −, Absence of agent;
+, presence of agent.
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Fig. 5.
PROK1 induces ERK 1/2 and COX-2 expression in first-trimester decidua. A, PROKR1
(red) and COX-2 (green) colocalize (yellow) to the glandular epithelium and a subset of
stromal cells in human endometrium (n = 5) and first-trimester decidua (n = 5;
representative sections shown, inset, negative control incubated with control IgG). B,
Treatment of first-trimester decidua explants with 40 nM PROK1 resulted in ERK1/2
phosphorylation (pERK), which was maximal at 30–45 min. C, ERK 1/2 phosphorylation
was measured in first-trimester decidua in response to the administration of vehicle or 40
nM PROK1 for 30 min in the presence or absence of pretreatment with YM254890 (Gq
inhibitor, lane 3), U73122 (PLC inhibitor, lane 4), PP2 (cSrc inhibitor, lane 5), AG1478
(EGFR inhibitor, lane 6), or PD98059 (MEK inhibitor, lane 7). PROK1-induced ERK 1/2
response was significantly inhibited in the presence of the above inhibitors. D, Treatment of
first-trimester decidua explants with 40 nM PROK1 resulted in increased expression of
COX-2, which was maximal at 6 h. E, PROK1-induced COX-2 mRNA expression was
inhibited by preincubation of first-trimester decidua with YM254890 (Gq inhibitor, lane 3),
U73122 (PLC inhibitor, lane 4), PP2 (cSrc inhibitor, lane 5), AG1478 (EGFR kinase
inhibitor, lane 6), or PD98059 (MEK inhibitor, lane 7). For B and C, a representative
Western immunoblot is shown, with semiquantitative analysis determined as described in
Materials and Methods. In all panels each bar represents mean ± SEM of at least five
experiments (*, P < 0.05). −, Absence of agent; +, presence of agent.
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TABLE 1
Taqman primer and probe sequences for COX-2, LIF, IL-6, IL-8, IL-11, and 18s
Gene Primers and probe (5′–3′)
PROK1 forward GTGCCACCCGGGCAG
PROK1 reverse AGCAAGGACAGGTGTGGTGC
PROK1 probe (FAM) ACAAGGTCCCCTTGTTCAGGAAACGCA
PROKR1 forward TCTTACAATGGCGGTAAGTCCA
PROKR1 reverse CTCTTCGGTGGCAGGCAT
PROKR1 probe (FAM) TGCAGACCTGGACCTCAAGACAATTGG
COX-2 forward CCTTCCTCCTGTGCCTGATG
COX-2 reverse ACAATCTCATTTGAATCAGGAAGCT
COX-2 probe (FAM) TGCCCGACTCCCTTGGGTGTCA
LIF forward TGGTGGAGCTGTACCGCATA
LIF reverse TGGTCCCGGGTGATGTTG
LIF probe (FAM) TCGTGTACCTTGGCACCTCCCTGG
IL-6 forward GCCGCCCCACACAGACA
IL-6 reverse CCGTCGAGGATGTACGGAAT
IL-6 probe (FAM) CCACTCACCTCTTCAGAACGAATTGACAAAC
IL-8 forward CTGGCCGTGGCTCTCTT
IL-8 reverse TTAGCACTCCTTGGCAAAACTG
IL-8 probe (FAM) CCTTCCTGATTTCTGCAGCTCTGTGTGAA
IL-11 forward CCCAGTTACCCAAGCATCCA
IL-11 reverse AGACAGAGAACAGGGAATTAAATGTGT
IL-11 probe (FAM) CCCCAGCTCTCAGACAAATCGCCC
18s forward CGGCTACCACATCCAAGGAA
18s reverse GCTGGAATTACCGCGGCT
18s probe (VIC) TGCTGGCACCAGACTTGCCCTC
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TABLE 2
Regulation of gene expression by PROK1 on activation of PROKR1
Gene symbol Gene product Mean fold change
ACSL4 Acyl-CoA synthetase long-chain family member 4 isoform 2 1.5
AKAP12 A-kinase anchor protein 12 isoform 2 2.8
AREG Amphiregulin preproprotein 5.3
BNC1 Basonuclin 1 2.4
CD44 CD44 antigen isoform 4 precursor 1.9
CORO1C Coronin 2.3
DAF Decay accelerating factor for complement 9.8
DCAMKL1 Doublecortin and CaM kinase-like 1 2.6
DKK1 Dickkopf homolog 1 8.5
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 1.9
DSCR1 Calcipressin 1 isoform c 5.2
DTR Diphtheria toxin receptor/heparin binding EGF like growth factor 3.6
DUSP1 Dual-specificity phosphatase 1 4.4
DUSP14 Dual-specificity phosphatase 14 1.9
DUSP4 Dual-specificity phosphatase 4 isoform 2 9.4
DUSP5 Dual-specificity phosphatase 5 7.2
EGR1 Early growth response 1 2.1
EIF2AK3 Eukaryotic translation initiation factor 2-α kinase 3 1.7
ENAH Enabled homolog 1.7
FGD6 RhoGEF and PH domain containing 6 1.8
GEM GTP-binding mitogen-induced T-cell protein 5.3
GREM1 Cysteine knot superfamily 1 12.4
HERC4 Hect domain and RLD 4 1.9
HMGB2 High-mobility group box 2 −1.6
IER3 Immediate early response 3 9.2
IL11 IL-11 precursor 19.8
IL6 IL-6 17.2
IL8 IL-8 precursor 9.7
KRTHA4 Type I hair keratin 4 5.8
LAMA3 Laminin-α3 subunit isoform 2 2.0
LIF Leukemia inhibitory factor 2.6
MAIL Molecule possessing ankyrin repeats induced by lipopolysaccharide 3.6
NR3C1 Nuclear receptor subfamily 3 1.6
NR4A1 Nuclear receptor subfamily 4, group A, member 1 isoform 7.0
NR4A2 Nuclear receptor subfamily 4, group A, member 2 isoform 4.3
PBEF1 Pre-B-cell colony enhancing factor 1 isoform 1.8
PTGS2 Prostaglandin-endoperoxide synthase 2 6.3
PTPRR Protein tyrosine phosphatase, receptor type, R 2.0
SCHIP1 Schwannomin interacting protein 1 2.0
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Gene symbol Gene product Mean fold change
SERPINE1 Plasminogen activator inhibitor-1 3.9
SLC20A2 Solute carrier family 20, member 2 1.9
STK38 liter Serine/threonine kinase 38 like 1.9
TMEM22 Transmembrane protein 22 1.8
TMPRSS2 Transmembrane protease, serine 2 − 2.1
TNFAIP1 TNF, α-induced protein 1 2.3
TRIB1 G-protein-coupled receptor induced protein 2.7
TRIB3 Tribbles 3 2.0
TXNIP Thioredoxin interacting protein − 3.0
ZNF165 Zinc finger protein 165 1.6
PROKR1-Ishikawa cells were treated with vehicle or 40 nM PROK1 for 8 h and subjected to gene array analysis on AB1700 and Affymetrix arrays
(n = 3 individual experiments). With application of adjusted P ≤ 0.05 on at least one platform, 49 genes were found to be differentially regulated
with 46 genes up-regulated and three genes down-regulated.
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